SLC5A2 and Hypomagnesemia: Hypomagnesemia is common in patients receiving SGLT2 inhibitors (i.e., those with DM, CKD, and CHF), with its incidence being 25% in T2DM [24], 14.7% in CKD [25], and 19–37% in heart failure [26].